Andrew Cole, MD
Epilepsy · Boston, MANPI 1043201502
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $183,847 of the $186,119 with a category attached, or 98.8%. Sage Therapeutics, LLC accounts for 90.7% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2020 at $84,569 and has fallen 95.2% since, to $4,053 in 2025. Among epilepsy clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 34 payments — averaging $5474.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sage Therapeutics, LLC$169K
- Eisai Inc.$4K
- Biocodex, Inc.$4K
- Takeda Pharmaceuticals U.S.A., Inc.$3K
- Vertex$3K
- Sanofi US Services Inc.$2K
- plus $2K from 6 others
Across 164 payments — averaging $2901.66 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$312K
- Neuropace, Inc.$64K
- Medtronic$46K
- AbbVie$28K
- Biogen$25K
- Takeda Pharmaceuticals U.S.A., Inc.$2K
What the payments were for
- Consulting fees$183,84799%
- Speaking & faculty fees$5750%
- Travel & lodging$9581%
- Food & beverage$7390%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sage Therapeutics, LLC | 13 | $168,720 |
| Eisai Inc. | 1 | $4,320 |
| Biocodex, Inc. | 4 | $4,053 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $3,000 |
| Vertex | 1 | $2,500 |
| Sanofi US Services Inc. | 3 | $1,845 |
| Aquestive Therapeutics, Inc. | 1 | $1,020 |
| UCB, Inc. | 4 | $240 |
| Neuropace, Inc. | 1 | $126 |
| Sunovion Pharmaceuticals Inc. | 1 | $125 |
| Jazz Pharmaceuticals Inc. | 1 | $86 |
| Greenwich Biosciences, Inc. | 2 | $85 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Zurzuvae$7,500
- Fycompa$4,320
- DIACOMIT$4,008
- RNS System$126
- APTIOM$125
How this compares
$186,119 in reported general payments places this provider in the 95th percentile of 28 epilepsy providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Levetiracetam | 53 | $3,219 |
| Lamotrigine | 50 | $1,495 |
| Oxcarbazepine | 28 | $1,281 |
| Zonisamide | 15 | $1,116 |
| Clonazepam | 11 | $14 |
Paid to pharmacies, not to this prescriber.
Other epilepsy in Boston
- Claire JacobsBoston$118K
- Ioannis KarakisBoston$56K
- Milena PavlovaBoston$23K
- Alice LamBoston$10K
- Rani SarkisBoston$6K
- Paula VoinescuBoston$5K
- Peter HadarBoston$413
- Niravkumar BarotBoston$352
- Ronald ThibertBoston$304
- Christopher McGrawBoston$294
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.